Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294413 | 0.88 | CA1 (0.51) | ALDH1A1TDP1HTTCA1CA2 | |
| SCHEMBL6294410 | 0.88 | CA1 (0.51) | ALDH1A1TDP1HTTCA1CA2 | |
| SCHEMBL6041193 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TDP1HTTTSHRLMNA | |
| SCHEMBL1525903 | 0.76 | CA1 (0.49) | ALDH1A1TDP1HTTCA1CA2 | |
| SCHEMBL19381536 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TDP1HTTCYP19A1LMNA | |
| SCHEMBL11819145 | 0.76 | ALDH1A1 (0.64) | ALDH1A1TDP1HTTACHECYP19A1 | |
| SCHEMBL4535383 | 0.76 | HSD17B10 (0.56) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1131658 | 0.73 | ALDH1A1 (0.62) | ALDH1A1TDP1HTTACHETSHR | |
| SCHEMBL28257783 | 0.73 | ALDH1A1 (0.58) | ALDH1A1TDP1HTTTSHRLMNA | |
| SCHEMBL10878837 | 0.72 | HTT (0.62) | ALDH1A1TDP1HTTCYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867197-B1 | Method of targeting conjugate molecules to mitochondria | MITOKOR (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | MITOKOR (US) | 2003-05-08 | — | — | US | disclosed |
| US-6171859-B1 | DEFECTIVE CYTOCHROME C OXIDASE; DIAGNOSING ALZHEIMER*S DISEASE | MITOKOR | 2001-01-09 | — | — | US | disclosed |
| US-6146831-A | CYBRID CELL LINE OF CULTURED CELLS HAVING GENOMIC AND MITOCHONDRIAL NUCLEIC ACIDS OF DIFFERENT BIOLOGICAL ORIGINS; FOR DRUG SCREENING AND EVALUATION OF THERAPY | MITOKOR (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0751951-A4 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0939832-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | Mitokor (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5840493-A | DIAGNOSIS OF LATE ONSET DIABETES BY DETECTION OF MUTATIONS IN ADENOSINE TRIPHOSPHATE SYNTHASE OR TRANSFER RNA (LYS) GENES IN A BIOLOGICAL SAMPLE; LABELLED NUCLEOTIDE SEQUENCES AS DETECTORS; ACCURACY | MITOKOR (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998017826-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | MITOKOR (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0751951-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | Mitokor (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026973-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4897503-A | ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY | TAIHO PHARMACEUTICAL (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | COX5A, MT-CO3, COX6A1 | ALDH1A1 489/4885TDP1 478/4885HTT 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.